Trials / Completed
CompletedNCT01034267
Safety Study of F2695 SR in Major Depressive Disorder
A Long-Term, Open-label Extension Study of F2695 SR in Adult Patients With Major Depressive Disorder
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 828 (actual)
- Sponsor
- Forest Laboratories · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the long- term safety of F2695-SR in the treatment of adults with major depressive disorder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | F2695 SR | Drug F2695 SR (flexible dose) to be given orally in capsule form once daily |
Timeline
- Start date
- 2009-12-01
- Primary completion
- 2012-06-01
- First posted
- 2009-12-17
- Last updated
- 2012-08-17
Locations
68 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01034267. Inclusion in this directory is not an endorsement.